New investment models and digital twin technologies are bridging gaps in rare disease drug development, where traditional funding and trial designs fall short. Patient-led funding and family offices provide capital, while regulators accept digital evidence to accelerate therapies for the more than 7,000 rare diseases with few approved treatments.
A recent global analysis shows oncology dominates clinical trial activity in 2025, while Phase II attrition rates dropped to 26%—the lowest in four years. The US remains the leader in investigator sites, but China is the fastest-growing market. Obesity research is poised to break into the top five most-studied diseases.
The global AI in clinical trials market is expected to grow from $2.09 billion currently to $18.62 billion by 2040, driven by enhanced patient recruitment, optimized trial designs, and automation that reduces time and costs in drug development.
